CSIMarket
 
Diamedica Therapeutics Inc   (NASDAQ: DMAC)
Other Ticker:  
 
 
Price: $6.3800 $0.12 1.917%
Day's High: $6.45 Week Perf: 6.69 %
Day's Low: $ 6.16 30 Day Perf: 16.85 %
Volume (M): 82 52 Wk High: $ 6.45
Volume (M$): $ 521 52 Wk Avg: $3.81
Open: $6.26 52 Wk Low: $2.14



 Market Capitalization (Millions $) 273
 Shares Outstanding (Millions) 43
 Employees 25
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Diamedica Therapeutics Inc
Diamedica Therapeutics Inc is a biopharmaceutical company that focuses on the development of innovative therapies for patients with neurological and cardiovascular diseases. The company aims to address unmet medical needs in these areas by leveraging their expertise in protein engineering and biotherapeutics. Their research and development efforts primarily involve the development of drugs that target specific disease mechanisms or pathways. Diamedica Therapeutics Inc is committed to improving patient outcomes and enhancing the quality of life for individuals suffering from these debilitating conditions.


   Company Address: 301 Carlson Parkway, Suite 210 Minneapolis 55305 MN
   Company Phone Number: 496-5454   Stock Exchange / Ticker: NASDAQ DMAC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.6%    
LLY        2.77% 
REGN   -0.96%    
TEVA   -1.47%    
VRTX   -5.72%    
VTRS   -3.42%    
• View Complete Report
   



Business Update

Advances in Clinical Trials and Financial Transparency DiaMedica Therapeutics at the Forefront of Ischemic Disease Tr...

Published Mon, Feb 10 2025 9:36 PM UTC

Abstract DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is strategically positioning itself within the healthcare sector through innovative approaches in treating severe ischemic diseases. Recent announcements regarding their participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference and the commencement of their...

Business Update

Embarking on New Frontiers in Maternal Healthcare The Quest of DiaMedica Therapeutics in Preeclampsia Treatment with ...

Published Thu, Nov 14 2024 3:58 AM UTC

Innovative Pursuits in Preeclampsia Treatment: DiaMedica Therapeutics Embarks on Phase 2 Trial of DM199 In the pursuit of advanced therapeutic interventions for preeclampsia (PE), a formidable condition prevalent in obstetric medicine, DiaMedica Therapeutics Inc. has embarked on a significant clinical investigation by dosing the first patient in an investigator-sponsored Pha...

Business Update

Pioneering Progress DiaMedica Therapeutics Doses First Patient in Phase 2 Trial for Preeclampsia Treatment

Published Wed, Nov 13 2024 10:29 PM UTC

In an exciting development for maternal health, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), the Minneapolis-based biopharmaceutical company renowned for its commitment to advancing treatments for severe ischemic diseases, has announced the dosing of its first patient in a Phase 2 clinical trial examining the efficacy of DM199 in the treatment of preeclampsia (PE). This novel...

Business Update

DiaMedica Therapeutics to Unveil Q3 2024 Financial Results and Strategic Update on November 14,

Published Wed, Nov 6 2024 1:36 PM UTC

DiaMedica Therapeutics Inc., a biopharmaceutical company based in Minneapolis and listed on the Nasdaq under the ticker DMAC, is poised to release its financial results for the third quarter of 2024. The financial report will be made available after the market closes on Wednesday, November 13, 2024. This announcement comes as the company continues its commitment to developin...

Business Update

Innovation in Preeclampsia Treatment DiaMedica Therapeutics Gains Regulatory Approval for Phase 2 Clinical Trial of D...

Published Wed, Oct 9 2024 12:47 PM UTC

AbstractPreeclampsia, a complex hypertensive disorder occurring during pregnancy, poses significant risks to maternal and fetal health. New therapeutic strategies to address this condition are urgently needed. DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on severe ischemic diseases, has recently received regulatory approval from the South ...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com